Navigation Links
Neuralstem ALS trial in multiple presentations at upcoming American Academy of Neurology meeting
Date:4/6/2011

ROCKVILLE, April 6, Maryland, 2011 Neuralstem, Inc. (NYSE Amex: CUR) announced that the Phase I safety trial of its human spinal cord stem cells (HSSCs) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is the subject of three presentations at the American Academy of Neurology (AAN) Annual Meeting, April 9-16th, in Honolulu, HI (http://www.aan.com/go/am11). Chief among these will be a presentation by Eva Feldman, M.D., Ph.D., who is an unpaid consultant to Neuralstem and the Principal Investigator in the ongoing ALS trial, entitled: "A Phase I, Open-Label, First-In-Human Feasibility and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis," at 2:00 PM, April 11th, (http://www.abstracts2view.com/aan/view.php?nu=AAN11L_P01.287). Dr. Feldman, who is also Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, will present interim safety data on the first nine patients in the study.

Dr. Feldman's presentation was also chosen to be highlighted in the "Scientific Program Highlights Plenary Session" mediated by the Chair of the AAN Science Committee at 5:15 on April 15th. Inclusion in this session is by invitation only; Dr. Feldman's presentation was considered by the committee to be in the top 5% of submitted abstracts, which numbered in the thousands.

"We are thrilled to receive this level of interest and review from our peers at this prestigious neurology conference," Dr. Feldman commented. "As a doctor who sees ALS patients in the clinic, I am particularly eager to share this promising research with the scientists and clinicians of the American Academy of Neurology who continue to battle this difficult disease for their patients."

In addition
'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Neuralstem files FDA application for first drug therapy
2. Neuralstem updates ALS clinical trial progress
3. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
4. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
5. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
6. Neuralstem updates clinical trial progress
7. Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network
8. Diabetes treatment may also provide protection against endometrial cancer
9. For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial
10. Clinical trial seeks to determine whether platelet-rich plasma can ease the pain of osteoarthritis
11. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research from ... apparently to blame for the surge. The researchers also found ... groups equally, with alarming increases in diabetes in blacks, Hispanics ... the April 15, 2014 issue of the Annals of ...
(Date:4/15/2014)... San Diego School of Medicine have identified a mechanism that ... disease and why the virus is able to persist in ... which infects an estimated 200 million people worldwide, attacks the ... cell,s innate ability to fight infection. It does this by ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have published ... Oral, and Craniofacial Manifestations." The complete review by researchers ... Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice ... J. Timothy Wright is published in the OnlineFirst portion ...
(Date:4/14/2014)... West Orange, NJ. April 10, 2014. John DeLuca, PhD, ... from Biogen Idec to study how persons with multiple ... "The Use of Actual Reality to Measure Everyday Life ... conduct this research. Dr. DeLuca is senior VP of ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Breaking bad mitochondria 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... a troubled existence due to memory loss. The situation plummets ... patients live in The United Kingdom and most of them ... happen to such patients; lack of mental stimulation, social activity ... despair. ,The study, published in the journal Nature, ...
... do not pose a health hazard to workers in ... of 28,000 people, published ahead of print in// Occupational ... electromagnetic fields of 50 to 60 Hz has been ... breast cancers. ,The researchers used the health ...
... life in Rajasthan Monday as the mercury hovered between 40-45 ... ,The roads wore a deserted look with people preferring ... there would be no respite from the heat wave. ... of Rajasthan with the day temperatures four to six degrees ...
... for children, we have already been told. But now UK ... ,Professor Lawrie Challis, head of the government's committee on ... distance from the embedded antennas. ,Challis, a retired ... a desktop computer, the transmitter will be in the tower. ...
... Satraplatin, a chemotherapy drug has recently been tested ... Patients and found //to have significant improvement in ... University on Phase III trial on Satraplatin has ... for Improvement in Progression-Free Survival ...
... imagine when the cost of the error is three lives! ... in bad light following the irrevocable error committed by a ... explained how a weighing error committed by a worker during ... of three people in the Pacific Northwest, who consumed the ...
Cached Medicine News:Health News:Dementia – Worse With a Dull Life. Keep Busy, and Active to Improve Memory, Study Recommend 2Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 2Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 3Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 4Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 5
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: